Abstract: A method for producing a lubricating base oil, comprising: performing a 13C-NMR analysis regarding an oil to be treated and selecting the oil based on a value for dividing an integrated value of a peak for a tertiary carbon atom by an integrated value of all peaks at 0 to 50 ppm, a value for dividing an integrated value of a peak for a carbon atom constituting a main chain by the integrated value of all peaks at 0 to 50 ppm, and a value for dividing an integrated value of a peak for a branched CH3 bonded to a fifth or the following carbon atom from a terminal carbon atom in the main chain by an integrated value of all peaks at 10 to 25 ppm, and obtaining a dewaxed oil by isomerization dewaxing of the oil selected in the first step, is disclosed.

Abstract: A method for producing a lubricating base oil, comprising: performing a 13C-NMR analysis regarding an oil to be treated and selecting the oil based on a value for dividing an integrated value of a peak for a tertiary carbon atom by an integrated value of all peaks at 0 to 50 ppm, a value for dividing an integrated value of a peak for a carbon atom constituting a main chain by the integrated value of all peaks at 0 to 50 ppm, and a value for dividing an integrated value of a peak for a branched CH3 bonded to a fifth or the following carbon atom from a terminal carbon atom in the main chain by an integrated value of all peaks at 10 to 25 ppm, and a obtaining a dewaxed oil by isomerization dewaxing of the oil selected in the first step, is disclosed.

Abstract: A subirrigation system 10 includes a water-impervious member 16, and keeps water content in soil of a cultivated land 200 in a proper state for growing a plant. The water-impervious member 16 is formed into an upper opening vessel shape, and has a water reserving function. Water is fed to an inner portion of the water-impervious member 16 from a water tank 12 via a feed water pipe 14, whereby a soil portion 26 in a gravitational water state is formed. A water level 28 of the gravitational water within the water-impervious member 16 is properly controlled to a desired water level by a water level controller 18 provided in the feed water pipe 14. The gravitational water within the water-impervious member 16 controlled to the desired water level is appropriately sucked up to the soil in an upper layer in accordance with a capillary phenomenon. Accordingly, a soil portion 30 in a capillary water state having proper water content is formed in the cultivated land 200.

Abstract: A subirrigation system 10 includes a water-impervious member 16, and keeps water content in soil of a cultivated land 200 in a proper state for growing a plant. The water-impervious member 16 is formed into an upper opening vessel shape, and has a water reserving function. Water is fed to an inner portion of the water-impervious member 16 from a water tank 12 via a feed water pipe 14, whereby a soil portion 26 in a gravitational water state is formed. A water level 28 of the gravitational water within the water-impervious member 16 is properly controlled to a desired water level by a water level controller 18 provided in the feed water pipe 14. The gravitational water within the water-impervious member 16 controlled to the desired water level is appropriately sucked up to the soil in an upper layer in accordance with a capillary phenomenon. Accordingly, a soil portion 30 in a capillary water state having proper water content is formed in the cultivated land 200.

Abstract: The present invention relates to a composition for prevention and treatment of kidney diseases comprising one or more effective component(s) of a PAR-2 activating agent which is able to activate PAR-2 and a pharmaceutically acceptable carrier. The present invention further relates to a method for prevention and treatment of kidney diseases comprising administration of a composition for prevention and treatment of kidney diseases containing a PAR-2 activating agent which is able to activate PAR-2 to patients suffering from kidney diseases, and also relates to the use of a PAR-2 activating agent which is able to activate PAR-2 for the manufacture of a composition for prevention and treatment of kidney diseases. The present invention furthermore relates to a method for screening an effective ingredient for prevention and treatment of kidney diseases comprising screening of the activating action of the test substance to PAR-2.

Abstract: The present invention provides a pharmaceutical composition by a novel action mechanism without serious side effects for delayed hypersensitivity and a screening method of the same. The invention also provides a novel assay method of inhibitors/suppressive agents of PAR-2. The invention relates to a pharmaceutical composition for delayed hypersensitivity containing one or two or more active ingredients selected from the group consisting of inhibitors of PAR-2 and suppressive agents of PAR-2 gene expression and a pharmaceutically acceptable carrier, and to a method for screening active ingredients for pharmaceutical composition for delayed hypersensitivity by contacting a subject substance with cells expressing PAR-2 and by determining expression or activity of PAR-2. The invention also relates to a method for detecting or quantifying actions of the subject substance for PAR-2 using cells expressing PAR-2 in a culture containing inositol.

Abstract: A logic optimization device refers to hierarchical circuit-design descriptions representing multiple layers of an integrated circuit, and decides whether or not each output terminal at each lower layer is connected with its upper layer. If an output terminal at a lower layer has been decided to be unconnected with its upper layer, the logic optimization device deletes from the hierarchical circuit-design descriptions an information part describing the output terminal, and deletes from the hierarchical circuit-design descriptions an information part describing an element at the lower layer connected with the deleted output terminal, thereby producing a gate-level net-list of an integrated circuit without ineffectual elements.

Abstract: The present invention relates to a composition for prevention and treatment of kidney diseases comprising one or more effective component(s) of a PAR-2 activating agent which is able to activate PAR-2 and a pharmaceutically acceptable carrier. The present invention further relates to a method for prevention and treatment of kidney diseases comprising administration of a composition for prevention and treatment of kidney diseases containing a PAR-2 activating agent which is able to activate PAR-2 to patients suffering from kidney diseases, and also relates to the use of a PAR-2 activating agent which is able to activate PAR-2 for the manufacture of a composition for prevention and treatment of kidney diseases. The present invention furthermore relates to a method for screening an effective ingredient for prevention and treatment of kidney diseases comprising screening of the activating action of the test substance to PAR-2.

Abstract: A semiconductor device includes a delay amount measuring unit, multiple delay sections and a correction signal generating unit. The delay amount measuring unit for measures an actual delay amount corresponding to a specified delay amount by supplying a clock signal with a known period to multiple 1-ns-delay strings with a preassigned delay amount, and by detecting phase variations of the clock signal by the 1-ns-delay strings. The delay sections includes a delay string capable of freely adjusting a connection number of its delay elements. The correction signal generating unit generates a correction signal for enabling each of the delay sections to correct the connection number of the delay strings such that each delay section has a desired delay amount, in accordance with the actual delay amount corresponding to the specified delay amount and measured by the delay measuring unit.

Abstract: A semiconductor device includes a delay amount measuring unit, multiple delay sections and a correction signal generating unit. The delay amount measuring unit for measures an actual delay amount corresponding to a specified delay amount by supplying a clock signal with a known period to multiple 1-ns-delay strings with a preassigned delay amount, and by detecting phase variations of the clock signal by the 1-ns-delay strings. The delay sections includes a delay string capable of freely adjusting a connection number of its delay elements. The correction signal generating unit generates a correction signal for enabling each of the delay sections to correct the connection number of the delay strings such that each delay section has a desired delay amount, in accordance with the actual delay amount corresponding to the specified delay amount and measured by the delay measuring unit.

Abstract: A logic optimization device refers to hierarchical circuit-design descriptions representing multiple layers of an integrated circuit, and decides whether or not each output terminal at each lower layer is connected with its upper layer. If an output terminal at a lower layer has been decided to be unconnected with its upper layer, the logic optimization device deletes from the hierarchical circuit-design descriptions an information part describing the output terminal, and deletes from the hierarchical circuit-design descriptions an information part describing an element at the lower layer connected with the deleted output terminal, thereby producing a gate-level net-list of an integrated circuit without ineffectual elements.

Abstract: After a logic verification is made in a low-hierarchical block, a logic verification is made in a high-hierarchical block circuit in a state that the low-hierarchical block is not the subject of comparison. Even if the number of input ports in the low-hierarchical block increases due to a change of the circuit, logical equivalence of the high-hierarchical circuit is verified by using equivalence information of the input ports.

Abstract: There is described a means of shortening of the time required for verification by a formal logic verification system which compares details of a circuit represented in the form of a register transfer level (RTL) description with details of the circuit represented in the form of a gate level netlist. Logical equivalence between an RTL description and a gate level netlist obtained through logical compilation of the RTL descriptions is verified. In a case where a plurality of blocks having the same function are included in the circuit, one of a plurality of descriptions that are included in the netlist and relate to the function is compared with the RTL description relating to the functional blocks (comparison {circle around (1)}). If one of the descriptions of the netlist has already been verified, a plurality of descriptions included in the netlist are compared with the description that is taken as the first reference description.

Abstract: A multiplication device for performing a multiplication operation on a multiplicand X and two fixed coefficients C1 and C2 where C1>C2. The multiplication device comprises a multiplier for multiplying multiplicand X and the average CA of the two fixed coefficients C1 and C2; a shift register for obtaining a sum of the multiplicand X data after being shifted up according to a position of a “1” bit in bit data where the bit data is the remainder coefficient obtained by subtracting average CA from fixed coefficient C1; and a selector for selecting a product obtained for one of the fixed coefficients C1 and C2. When the fixed coefficient C1 is selected, the selector outputs the sum of the product returned by the multiplier and the accumulated value obtained by the shift register; when fixed coefficient C2 is selected, the selector outputs the difference of the product returned by the multiplier minus the accumulated value obtained by the shift register.

Abstract: This invention relates to a flavone derivative represented by the formula (1) or a salt thereof, and also to a medicine containing the same. ##STR1## wherein A represents H, halogen, phenyl, naphthyl, a group of the formula (2) in which X is H or halogen, B is --CH.dbd.CH--, --CH.dbd.N--, --N(R.sup.7)-- (R.sup.7 : lower alkyl or alkoxyalkyl), --O-- or --S--; W represents a single bond, --CH.sub.2 O-- or --CH.dbd.CH--; at least one of R.sup.1 to R.sup.4 represents --COOH, --CN, alkyloxycarbonyl, tetrazolyl or --CONHR.sup.8 (R.sup.8 : H, lower alkyl or phenylsulfonyl), the remainder thereof individually represent H, halogen, --OH, lower alkyl or lower alkoxyl; R.sup.5 represents H, --OH, lower alkoxyl, --O(CH.sub.2).sub.m NR.sup.9 R.sup.10 (R.sup.9,R.sup.10 : H or lower alkyl, or coupled together with the adjacent N to form a phthalimido group; m: 1-5), or a group of the formula (3) (n: 1-5, l: 2-3; and R.sup.6 represents H, halogen, lower alkyl or lower alkoxyl.

Abstract: This invention relates to a diamine derivative represented by the following formula (1) or a salt thereof. wherein R.sup.1 represents H, OH, an aralkyloxy group or a halogen atom; R.sup.2 represents H or a lower alkyl group; A represents --C(R.sup.3).dbd.CH--, --CH.dbd.N--, --N(R.sup.4)--, R.sup.3 being H or OH, R.sup.4 being a lower alkyl group or an alkoxyalkyl group, --O--, or --S--; B represents a single bond, --C(R.sup.5)(R.sup.6)--(CH.sub.2).sub.k --, R.sup.5 and R.sup.6 being H or a lower alkyl group, and k being a value of from 0 to 2, --S(O).sub.q CH(R.sup.7), or --CH.dbd.CH--; E represents a single bond or --(CH.sub.2).sub.3 --; W and Y individually represent --CH.sub.2 -- or --CO--; Z represents O or S; and m is a value of 2 or 3, and n is a value of from 1 to 4; with the proviso that E is --(CH.sub.2).sub.3 -- when B is a single bond and E is a single bond when B is a group other than a single bond.

Abstract: The present invention is directed to a tetrazole derivative represented by the following formula (1) or a salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, a substituted or unsubstituted alkoxy group, or a substituted or unsubstituted alkanoyloxy group; R.sup.3 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group; A represents a methyleneoxy group or a vinylene group; B represents a substituted or unsubstituted quinolyl group, a substituted or unsubstituted quinazolyl group, or a substituted or unsubstituted benzimidazolyl group; and a broken line indicates that there may be a double bond; and to a medicine containing the compound as an active ingredient. The medicine according to the present invention is endowed with excellent antileukotriene activity and antihistaminic activity, and is useful for the prevention and treatment of, for example, asthma.

Abstract: The present invention is directed to a tetrazole derivative represented by the following formula (1) or a salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, a substituted or unsubstituted alkoxy group, or a substituted or unsubstituted alkanoyloxy group; R.sup.3 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group; A represents a methyleneoxy group or a vinylene group; Z represents a substituted or unsubstituted benzimidazolyl group; and a broken line indicates that there may be a double bond; and to a medicine containing the compound as an active ingredient. The medicine according to the present invention is endowed with excellent antileukotriene activity and antihistaminic activity, and is useful for the prevention and treatment of, for example, asthma.

Abstract: The present invention is directed to a piperidine derivative represented by the following formula (1) or a salt thereof: ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 individually represent hydrogen atoms, etc., Y represents ##STR2## B represents a single bond, an alkylene group, --S--CH.sub.2 --, or --CH.dbd.CH--, E represents a single bond or a trimethylene group, Z represents an oxygen atom, etc., and n represents a number between 2 and 5 inclusive; and to a medicine containing the compound. The medicine according to the present invention is endowed with excellent anti-histaminic activity and antileukotriene activity, and exhibits reduced side effects such as drowsiness.

Abstract: This invention relates to chalcone derivatives represented by the following formula (1): wherein A represents a phenyl group, a quinolyl group or the like, W represents a vinylene group or the like, and R.sup.1 to R.sup.5 each independently represent a carboxyl, cyano, alkyloxycarbonyl or like group, or salts of the chalcone derivatives, and also to drugs containing them as effective ingredients. These compounds have excellent cys-LT receptor antagonism, and are useful as antiallergic agents or the like.